Get the Stockscreener App
2.00
6.98%
-0.15
Traws Pharma Inc stock is traded at $2.00, with a volume of 71,480.
It is down -6.98% in the last 24 hours and up +26.58% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
See More
Previous Close:
$2.15
Open:
$2.18
24h Volume:
71,480
Relative Volume:
0.36
Market Cap:
$15.98M
Revenue:
$2.85M
Net Income/Loss:
$93.35M
P/E Ratio:
0.0831
EPS:
24.0802
Net Cash Flow:
$-19.47M
1W Performance:
-0.99%
1M Performance:
+26.58%
6M Performance:
+6.38%
1Y Performance:
-24.53%
1-Day Range:
$1.88
$2.18
1-Week Range:
$1.88
$2.29
52-Week Range:
$0.97
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.00 | 15.98M | 2.85M | 93.35M | -19.47M | 24.08 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | H.C. Wainwright | Buy |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
Published on: 2026-03-23 16:58:08 - baoquankhu1.vn
Traws Pharma (TRAW) Expected to Announce Earnings on Monday - Defense World
Aug Weekly: Whats the analyst consensus on Traws Pharma IncMarket Risk Analysis & High Win Rate Trade Tips - baoquankhu1.vn
Traws Pharma reports phase 2 COVID-19 data, flu program update - MSN
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones - MSN
Director at Traws Pharma (TRAW) receives grant of 33,435 stock options - Stock Titan
Traws Pharma (TRAW) director granted 31,258 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) director granted 33,435 stock options at $1.60 strike - Stock Titan
Traws Pharma (TRAW) awards CEO 231,336 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) awards 118,367 stock options to Chief Science Officer - Stock Titan
Traws Pharma (TRAW) COO receives grant of 96,899 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) awards 33,435 stock options to director Jack Stover - Stock Titan
Traws Pharma (TRAW) CMO awarded 108,854 stock options at $1.60 - Stock Titan
Traw Pharma director granted 33,435 stock options | TRAW SEC FilingForm 4 - Stock Titan
Will Traws Pharma Inc. (0T20) stock draw ESG focused fundsWeekly Profit Summary & High Accuracy Investment Signals - Naître et grandir
TRAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cash per share of Traws Pharma, Inc. – FWB:0T20 - TradingView
TRAW SEC FilingsTraws Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Traws Pharma Reports Phase 2 COVID-19 Data, Flu Program Update - MyChesCo
Traws Pharma (NASDAQ:TRAW) Trading Down 11.2% – Here’s What Happened - Defense World
Insider Sell: How much upside does Traws Pharma Inc haveTrade Entry Report & Accurate Intraday Trading Signals - baoquankhu1.vn
TRAWTraws Pharma Latest Stock News & Market Updates - Stock Titan
Traws Pharma Reports Differentiated COVID-19 and Influenza Antiviral Progress - Contagion Live
Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold By Investing.com - Investing.com South Africa
Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold - Investing.com
Traws Pharma Highlights Positive Ratutrelvir Phase 2 COVID-19 Data - TipRanks
Traws Pharma Stock Plunges As FDA Halts TXM IND - RTTNews
Traws Pharma completes Phase 2 ratutrelvir analysis; tivoxavir tablet shows 28-day influenza protection potential - TradingView
Traws Pharma completes analysis of ratutrelvir clinical study in Paxlovid®-eligible and ineligible Covid-19 patients - marketscreener.com
Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients - TradingView
Traws Pharma Reports Completed Clinical Results of Ratutrelvir Showing Differentiated Profile Compared to PAXLOVID® with Fewer Adverse Events and No Viral Rebounds - Quiver Quantitative
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - GlobeNewswire
Ayrton Capital LLC Reduces Stake in Traws Pharma Inc - GuruFocus
Squadron funds disclose 8.9% Traws Pharma (TRAW) ownership in 13G/A filing - Stock Titan
Traws Pharma advances antiviral pipeline with multiple regulatory submissions - MSN
TRAW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can Traws Pharma Inc. stock rebound after recent weaknessJuly 2025 Decliners & Technical Buy Zone Confirmations - mfd.ru
How rising interest rates impact Traws Pharma Inc. stockMarket Volume Summary & Free Technical Confirmation Trade Alerts - mfd.ru
Aug EndMonth: Will RSVR outperform tech stocks2025 Key Lessons & Safe Swing Trade Setups - baoquankhu1.vn
Why Traws Pharma Inc. stock could benefit from AI revolution - mfd.ru
Published on: 2026-02-03 21:55:07 - baoquankhu1.vn
LADENBURG THALM/SH SH Upgrades Traws Pharma (NASDAQ:TRAW) to Strong-Buy - Defense World
TRAW stock slides in volatile session – what’s the latest on its phase 2 trial for COVID-19 treatment? - MSN
Traws completes enrollment in phase 2 COVID-19 drug study By Investing.com - Investing.com Canada
Traws Pharma stock soars after completing COVID-19 treatment study By Investing.com - Investing.com South Africa
Traws Pharma stock soars after completing COVID-19 treatment study - Investing.com
TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? - Stocktwits
Traws Pharma (TRAW) Completes Enrollment in Phase 2 COVID-19 Stu - GuruFocus
Traws Pharma Completes Phase 2 Enrollment for COVID Candidate - TipRanks
Traws completes enrollment in phase 2 COVID-19 drug study - Investing.com
Traws Pharma Inc Stock (TRAW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):